03/13/2023
Alembic receives FDA nod for fluorouracil injection
The drug is indicated for the treatment of patients with adenocarcinoma of the colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma and pancreatic adenocarcinoma.
Alembic has received the green light from the Food and Drug Administration for fluorouracil injection, the generic version of the drug manufactured by Spectrum Pharmaceuticals, Inc.
Fluorouracil injection is indicated for the treatment of patients with adenocarcinoma of the colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma and pancreatic adenocarcinoma.
[Read more: Alembic rolls out generic Hygroton]
Fluorouracil injection has a market value of roughly $5 million, according to IQVIA.